EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients

Yam, Irene; Lam, David Chi‐Leung; Chan, Ka‐Kui; Ho, J. C.; Ip, Mary S.M.; Lam, Wah‐Kit; Chan, TK; Chan, Vivian

doi:10.1097/jto.0b013e3182558198

Cited by 42 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transl Lung Cancer Res 2016;5(6):695-708 tlcr.amegroups.com the point mutation L798I, never isolated before neither in vitro nor in vivo (21,22). L798 residue is located nearby C797 and its modification could theoretically interfere with drug binding.…”

Section: Other Egfr Mutationsmentioning

confidence: 99%

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Minari

Bordi

Tiseo

2016

Transl. Lung Cancer Res.

163

161

View full text Add to dashboard Cite

show abstract

Section: Other Egfr Mutationsmentioning

confidence: 99%

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Minari

Bordi

Tiseo

2016

Transl. Lung Cancer Res.

163

161

View full text Add to dashboard Cite

show abstract

“…CfDNA recently attracted growing interest in oncology for multipurpose use (11). It has been considered as a prognostic and predictive biomarker (12,13), and as a "liquid biopsy" to perform noninvasive testing for biomarker detection (14)(15)(16)(17)(18)(19)(20). However, the main challenge remains technical because, in many cases, tumor DNA (tDNA) may only represent a very small fraction of cfDNA (21,22).…”

Section: Introductionmentioning

confidence: 99%

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

Couraud

Vaca-Paniagua

Villar

et al. 2014

Clinical Cancer Research

197

155

View full text Add to dashboard Cite

Purpose: Tumor somatic mutation analysis is part of the standard management of metastatic lung cancer. However, physicians often have to deal with small biopsies and consequently with challenging mutation testing. Circulating free DNA (cfDNA) is a promising tool for accessing the tumor genome as a liquid biopsy. Here, we evaluated next-generation sequencing (NGS) on cfDNA samples obtained from a consecutive series of patients for the screening of a range of clinically relevant mutations.Experimental Design: A total of 107 plasma samples were collected from the BioCAST/IFCT-1002 lung cancer study (never-smokers cohort). Matched tumor DNA (tDNA) was obtained for 68 cases. Multiplex PCR-based assays were designed to target specific coding regions in EGFR, KRAS, BRAF, ERBB2, and PI3KCA genes, and amplicon sequencing was performed at deep coverage on the cfDNA/tDNA pairs using the NGS IonTorrent Personal Genome Machine Platform.Results: CfDNA concentration in plasma was significantly associated with both stage and number of metastatic sites. In tDNA, 50 mutations (36 EGFR, 5 ERBB2, 4 KRAS, 3 BRAF, and 2 PIK3CA) were identified, of which 26 were detected in cfDNA. Sensitivity of the test was 58% (95% confidence interval, 43%-71%) and the estimated specificity was 87% (62%-96%).Conclusion: These data demonstrate the feasibility and potential utility of mutation screening in cfDNA using IonTorrent NGS for the detection of a range of tumor biomarkers in patients with metastatic lung cancer. Clin Cancer Res; 20(17); 4613-24. Ó2014 AACR.

show abstract

“…A more simple, inexpensive and robust arraybased method enabled the efficient monitoring of multiple EGFR mutations in plasma cfDNA during TKI therapy of NSCLC patients. However, only 56 % of patients with response had non-detectable values and only 44 % with progression had an EGFR increase while other resistance mechanisms were not covered by this technique [141]. By use of other approaches, EGFR mutations frequency on plasma DNA was reported to decrease during chemotherapy and to correlate with response to therapy [142].…”

Section: Genetic Changes In Cfdnamentioning

confidence: 97%

CNAPS in Therapy Monitoring

Holdenrieder

2014

Advances in Predictive, Preventive and Personalised Medicine

View full text Add to dashboard Cite

Monitoring of disease state and of therapy response is highly relevant for efficient patient management. Monitoring tools comprise observation of clinical signs and performing specific examinations such as imaging or blood analyses. This review focusses on the relevance of blood-based biomarker monitoring by circulating nucleic acids for diverse indications that is exemplified on patients who develop or suffer from cancer disease. These indications include (i) screening of patient groups who have a risk to develop a disease, (ii) monitoring response to local or systemic therapies in patients with a defined diagnosis and (iii) early detection of disease recurrence after the primary therapy has ended. Useful biomarkers have to fulfill the highest methodical, pre-analytical and clinical quality criteria and have to be implemented in standardized patient management procedures. The current situation of circulating nucleic acids is summarized on the levels of genetic, epigenetic, transcript, non-coding RNA and nucleosome markers and an outlook is presented as to how these markers can be integrated into a future strategy that enables a personalized management of the patients.

show abstract

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients

Abstract: The EGFR array provides a sensitive, inexpensive, and robust method for monitoring non-small-cell lung cancer patients' response to TKI, and obviates the need of repeated lung biopsy.

Cited by 42 publications

References 33 publications

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

CNAPS in Therapy Monitoring

Contact Info

Product

Resources

About